A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphome (FL)
Research Grant
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
May 1, 2014
End Date
April 30, 2022
Administered By
Duke Cancer Institute
Awarded By
The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership
Start Date
May 1, 2014
End Date
April 30, 2022